EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences
Galderma will present 19 abstracts, including two oral presentations, at the 2026 EADV Congress, with new data on skin diseases, skin longevity and real-world patient experiences New analyses from the Nemluvio® (nemolizumab) clinical development program will explore long-term data, in line with Galderma’s commitment to improving the outcomes that matter most to patients1-7 Galderma will […]
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
